Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda
about
Untangling the Gordian knot of HIV, stress, and cognitive impairmentDepression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda.Screening for HIV-associated peripheral neuropathy in resource-limited settingsBrain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsEpidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.Neurological and psychiatric adverse effects of antiretroviral drugs.Incident neuropathy in HIV-infected patients on HAARTHIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda.Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study.Neurology and the Global HIV Epidemic.Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapyUptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia.Reasons for Missing Antiretroviral Therapy: Results from a Multi-Country Study in Tanzania, Uganda, and ZambiaLongitudinal neuropsychological test performance among HIV seropositive individuals in Uganda.Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospitalRisk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaoundé-CameroonIncreased incidence of symptomatic peripheral neuropathy among adults receiving stavudine- versus zidovudine-based antiretroviral regimens in Kenya.Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect.Does antiretroviral therapy improve HIV-associated cognitive impairment? A quantitative review of the literature.HIV-associated sensory neuropathy: risk factors and genetics.Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.Painful HIV-associated sensory neuropathy.Evolution of sensory neuropathy after initiation of antiretroviral therapy.A normative study of the color trails test in the Greek population.Current perspectives on HIV-related pain and its management: insights from sub-Saharan Africa.Biosynthesis of nucleoside analogues via thermostable nucleoside phosphorylase.Evaluation of Adverse Drug Reaction Profile of Drugs Used as First-Line Antiretroviral Therapy
P2860
Q28067483-71E8BF4F-778D-44E9-AF73-199D75ACD45EQ33600252-EECC5EEA-C61C-481F-BD41-5B452F09D7D6Q33603950-C77B7FFB-DC12-4FA2-80DC-1430FA8E7BB5Q33614467-9236A645-8006-4EBD-8B2B-2DAD551849EAQ33890060-0E8C9E8A-64F6-49F8-9B8E-510603946719Q34039419-659163CA-8643-42C3-AAB5-A4D5BCD3B846Q34100209-F00CDE5A-9286-453F-AE92-14AD34545AB2Q34135328-0BAD3B8D-FFE1-4AD5-A54A-E2E3486A7DD2Q35089902-010A06D9-3E52-4EBF-AC63-BD5EF4871188Q35149362-7CEF61A4-9567-4506-B328-C70103175FB9Q35164547-0B28AE88-12EB-404A-8AC8-0D3A7BC3737FQ35217508-CFE1D4B3-2714-4DD3-8074-6BF651E40120Q35898792-28801458-B835-4AB4-AA7E-B8B12B3B4E4DQ36597858-5F51A32A-A027-4C4B-A40C-6E942C1DA703Q36865445-DC82EDFC-CFF5-4120-B3B7-D1857EF3DDD0Q37001750-927CA803-D240-4B3C-9958-B01FBC25750CQ37053758-2F696DC1-9879-439F-83CD-B86194521C3BQ37659348-11C6AF6F-BC0B-41E1-8A2F-FBC658CCFF89Q37911001-9BD6E415-6227-4D9B-8EB6-D4452525D84DQ37988382-B06524E3-3C60-4C88-A45D-B5A4A658F5C4Q37999051-2CD6C402-5E79-4338-93E4-D9FBF8A43FB3Q38197249-2B6CE799-9A46-4EC4-9D2F-3163D0B8F01BQ40179291-C958C75A-11D4-4611-9117-C8D37FC2A0ABQ48181060-4AE12870-E288-4D48-8616-580728B4A19FQ48810942-0F053C04-D0B4-4C2C-9C35-6AFAE30B1A32Q54323278-5B732709-89FA-4318-8CDD-F85CFB546E62Q58803006-15C7BBCB-C32B-4191-9CB3-897CD2F3ABFD
P2860
Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefits and risks of stavudin ...... ologic complications in Uganda
@en
Benefits and risks of stavudin ...... logic complications in Uganda.
@nl
type
label
Benefits and risks of stavudin ...... ologic complications in Uganda
@en
Benefits and risks of stavudin ...... logic complications in Uganda.
@nl
prefLabel
Benefits and risks of stavudin ...... ologic complications in Uganda
@en
Benefits and risks of stavudin ...... logic complications in Uganda.
@nl
P2093
P2860
P1433
P1476
Benefits and risks of stavudin ...... ologic complications in Uganda
@en
P2093
D B Clifford
E Katabira
K Robertson
N Nakasujja
P2860
P304
P356
10.1212/01.WNL.0000339042.96109.86
P407
P577
2009-01-01T00:00:00Z